Benjamin Garmezy, MD

Financial relationships

  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    Abbvie
    Topic: 
    Research Funding
    Date added: 
    09/13/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    Accutar
    Topic: 
    Research Funding
    Date added: 
    09/13/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    Arcus
    Topic: 
    Research Funding
    Date added: 
    09/13/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    AstraZeneca
    Topic: 
    Research Funding
    Date added: 
    09/13/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    AVEO
    Topic: 
    Research Funding and Consulting - Institution
    Date added: 
    09/13/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    CRISPR Therapeutics
    Topic: 
    Research Funding
    Date added: 
    09/13/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    Exelixis
    Topic: 
    Research Funding and Consulting - Institution
    Date added: 
    09/13/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    Genetech/Roche
    Topic: 
    Research Funding
    Date added: 
    09/13/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    Harbour BioMed
    Topic: 
    Research Funding
    Date added: 
    09/13/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Other
    Ineligible company: 
    IDEAYA Biosciences
    Topic: 
    Research Funding
    Date added: 
    09/13/2023

Pages

Return to PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice